Orion Biotech Opportunities - Units (1 Ord Share Class A & 1/5 War) EBIT

The latest EBIT for ORIAU is $-900K as of December 2022. That compares with $-630K in the prior-year period — down 43.2% year over year. That is above the sector sector average of $-69M. Investors often review this figure alongside Orion Biotech Opportunities - Units (1 Ord Share Class A & 1/5 War)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, ORIAU's EBIT moved from $-630K to $-900K — a 43.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Orion Biotech Opportunities - Units (1 Ord Share Class A & 1/5 War)'s operating scale or balance-sheet position.

Against its sector companies, ORIAU currently prints $-900K for EBIT, while the sector average sits near $-69M. That is roughly 98.7% above the sector mean. Large gaps often invite a closer look at Orion Biotech Opportunities - Units (1 Ord Share Class A & 1/5 War)'s growth, margins, and balance sheet.

A EBIT figure of $-900K for ORIAU is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-69M. Explore the charts below for those layers of context.

After noting ORIAU's EBIT ($-900K), review year-over-year change from $-630K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.